Allison Naleway to United States
This is a "connection" page, showing publications Allison Naleway has written about United States.
Connection Strength
2.133
-
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years. JAMA. 2024 02 06; 331(5):408-416.
Score: 0.124
-
CASCADIA: a prospective community-based study protocol for assessing SARS-CoV-2 vaccine effectiveness in children and adults using a remote nasal swab collection and web-based survey design. BMJ Open. 2023 Jul 14; 13(7):e071446.
Score: 0.119
-
Medically Attended Influenza During Pregnancy in the 2019-2020 and 2020-2021 Influenza Seasons. Obstet Gynecol. 2022 11 01; 140(5):874-877.
Score: 0.113
-
Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States. JAMA Netw Open. 2022 09 01; 5(9):e2233273.
Score: 0.112
-
Influenza Vaccination During Pregnancy: Influenza Seasons 2002-2012, Vaccine Safety Datalink. Am J Prev Med. 2016 Apr; 50(4):480-488.
Score: 0.070
-
Monovalent H1N1 influenza vaccine safety in pregnant women, risks for acute adverse events. Vaccine. 2014 Sep 03; 32(39):4985-92.
Score: 0.064
-
Uptake, coverage, and completion of quadrivalent human papillomavirus vaccine in the vaccine safety Datalink, July 2006-June 2011. J Adolesc Health. 2013 Nov; 53(5):637-41.
Score: 0.061
-
Identifying pregnancy episodes, outcomes, and mother-infant pairs in the Vaccine Safety Datalink. Vaccine. 2013 Jun 12; 31(27):2898-903.
Score: 0.059
-
Risk of immune hemolytic anemia in children following immunization. Vaccine. 2009 Dec 09; 27(52):7394-7.
Score: 0.046
-
Delivering influenza vaccine to pregnant women. Epidemiol Rev. 2006; 28:47-53.
Score: 0.036
-
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. Lancet. 2024 Oct 19; 404(10462):1547-1559.
Score: 0.032
-
Disparities in COVID-19 vaccination receipt by race, ethnicity, and social determinants of health among a large patient population in a network of community-based healthcare centers. Vaccine. 2024 Oct 24; 42(24):126288.
Score: 0.032
-
Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023. J Infect Dis. 2024 Jul 25; 230(1):141-151.
Score: 0.032
-
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged =18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 28; 73(12):271-276.
Score: 0.031
-
Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines. Vaccine. 2023 09 07; 41(39):5678-5682.
Score: 0.030
-
Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months-5 Years - VISION Network, United States, July 2022-June 2023. MMWR Morb Mortal Wkly Rep. 2023 Aug 18; 72(33):886-892.
Score: 0.030
-
Smallpox vaccine: the good, the bad, and the ugly. Clin Med Res. 2003 Apr; 1(2):87-92.
Score: 0.029
-
Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial. Clin Infect Dis. 2023 02 08; 76(3):e1168-e1176.
Score: 0.029
-
Rotavirus Vaccine Impact Within an Integrated Healthcare Delivery System in the United States. J Pediatric Infect Dis Soc. 2022 Dec 28; 11(12):586-589.
Score: 0.029
-
Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers. JAMA. 2022 10 18; 328(15):1523-1533.
Score: 0.028
-
Travelers and travel vaccines at six health care systems in the Vaccine Safety Datalink. Vaccine. 2022 09 29; 40(41):5904-5911.
Score: 0.028
-
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 18; 71(11):422-428.
Score: 0.027
-
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 04; 71(9):352-358.
Score: 0.027
-
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18; 71(7):255-263.
Score: 0.027
-
Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-Nine States, January-September 2021. Am J Transplant. 2022 01; 22(1):306-314.
Score: 0.027
-
Monitoring vaccine safety using the vaccine safety Datalink: Assessing capacity to integrate data from Immunization Information systems. Vaccine. 2022 01 31; 40(5):752-756.
Score: 0.027
-
A multi-country investigation of influenza vaccine coverage in pregnant individuals, 2010-2016. Vaccine. 2021 12 20; 39(52):7598-7605.
Score: 0.026
-
Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
Score: 0.026
-
Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19-Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance - Nine States, June-August 2021. MMWR Morb Mortal Wkly Rep. 2021 09 17; 70(37):1291-1293.
Score: 0.026
-
COVID-19 Vaccination Coverage Among Insured Persons Aged =16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 16; 70(28):985-990.
Score: 0.026
-
COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 8, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jun 18; 70(24):895-899.
Score: 0.026
-
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 02; 70(13):495-500.
Score: 0.025
-
Evaluating the Association of Stillbirths After Maternal Vaccination in the Vaccine Safety Datalink. Obstet Gynecol. 2020 12; 136(6):1086-1094.
Score: 0.025
-
SARS-CoV-2 Infection Among Hospitalized Pregnant Women: Reasons for Admission and Pregnancy Characteristics - Eight U.S. Health Care Centers, March 1-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 23; 69(38):1355-1359.
Score: 0.024
-
Survey of influenza vaccine knowledge, attitudes, and beliefs among pregnant women in the 2016-17 season. Vaccine. 2020 02 24; 38(9):2202-2208.
Score: 0.023
-
Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics. 2019 12; 144(6).
Score: 0.023
-
Incidence of Herpes Zoster Among Children: 2003-2014. Pediatrics. 2019 07; 144(1).
Score: 0.022
-
Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination. Vaccine. 2019 06 27; 37(29):3918-3924.
Score: 0.022
-
Vaccine safety in HIV-infected adults within the Vaccine Safety Datalink Project. Vaccine. 2019 05 31; 37(25):3296-3302.
Score: 0.022
-
Infant Hospitalizations and Mortality After Maternal Vaccination. Pediatrics. 2018 03; 141(3).
Score: 0.020
-
Estimated rates of influenza-associated outpatient visits during 2001-2010 in 6 US integrated healthcare delivery organizations. Influenza Other Respir Viruses. 2018 01; 12(1):122-131.
Score: 0.020
-
Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults. BMC Pulm Med. 2017 Dec 16; 17(1):208.
Score: 0.020
-
Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy. Obstet Gynecol. 2017 09; 130(3):599-608.
Score: 0.020
-
Maternal Tdap vaccination and risk of infant morbidity. Vaccine. 2017 06 22; 35(29):3655-3660.
Score: 0.019
-
Identifying birth defects in automated data sources in the Vaccine Safety Datalink. Pharmacoepidemiol Drug Saf. 2017 Apr; 26(4):412-420.
Score: 0.019
-
Risk of Preterm or Small-for-Gestational-Age Birth After Influenza Vaccination During Pregnancy: Caveats When Conducting Retrospective Observational Studies. Am J Epidemiol. 2016 08 01; 184(3):176-86.
Score: 0.018
-
Demographic characteristics of members of the Vaccine Safety Datalink (VSD): A comparison with the United States population. Vaccine. 2015 Aug 26; 33(36):4446-50.
Score: 0.017
-
Reduction in Human Papillomavirus Vaccine Type Prevalence Among Young Women Screened for Cervical Cancer in an Integrated US Healthcare Delivery System in 2007 and 2012-2013. J Infect Dis. 2015 Dec 15; 212(12):1970-5.
Score: 0.017
-
Risk of Herpes Zoster and Disseminated Varicella Zoster in Patients Taking Immunosuppressant Drugs at the Time of Zoster Vaccination. Mayo Clin Proc. 2015 Jul; 90(7):865-73.
Score: 0.017
-
Safety of measles-containing vaccines in 1-year-old children. Pediatrics. 2015 Feb; 135(2):e321-9.
Score: 0.016
-
Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996-2006. Vaccine. 2015 Jan 03; 33(2):382-7.
Score: 0.016
-
The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. Vaccine. 2014 Sep 22; 32(42):5390-8.
Score: 0.016
-
Receipt of pertussis vaccine during pregnancy across 7 Vaccine Safety Datalink sites. Prev Med. 2014 Oct; 67:316-9.
Score: 0.016
-
Timely versus delayed early childhood vaccination and seizures. Pediatrics. 2014 Jun; 133(6):e1492-9.
Score: 0.016
-
Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season. Pharmacoepidemiol Drug Saf. 2014 May; 23(5):548-53.
Score: 0.015
-
Risk of intussusception after monovalent rotavirus vaccination. N Engl J Med. 2014 Feb 06; 370(6):513-9.
Score: 0.015
-
Safety of the yellow Fever vaccine: a retrospective study. J Travel Med. 2013 Nov-Dec; 20(6):368-73.
Score: 0.015
-
Further evidence for bias in observational studies of influenza vaccine effectiveness: the 2009 influenza A(H1N1) pandemic. Am J Epidemiol. 2013 Oct 15; 178(8):1327-36.
Score: 0.015
-
Mortality rates and cause-of-death patterns in a vaccinated population. Am J Prev Med. 2013 Jul; 45(1):91-97.
Score: 0.015
-
Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. Vaccine. 2013 May 24; 31(22):2578-83.
Score: 0.015
-
A population-based cohort study of undervaccination in 8 managed care organizations across the United States. JAMA Pediatr. 2013 Mar 01; 167(3):274-81.
Score: 0.014
-
Maternal safety of trivalent inactivated influenza vaccine in pregnant women. Obstet Gynecol. 2013 Mar; 121(3):519-25.
Score: 0.014
-
Vaccination site and risk of local reactions in children 1 through 6 years of age. Pediatrics. 2013 Feb; 131(2):283-9.
Score: 0.014
-
Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population. Clin Infect Dis. 2013 Feb; 56(3):315-21.
Score: 0.014
-
Assessing the safety of influenza immunization during pregnancy: the Vaccine Safety Datalink. Am J Obstet Gynecol. 2012 Sep; 207(3 Suppl):S47-51.
Score: 0.014
-
Patterns in influenza antiviral medication use before and during the 2009 H1N1 pandemic, Vaccine Safety Datalink Project, 2000-2010. Influenza Other Respir Viruses. 2012 Nov; 6(6):e143-51.
Score: 0.014
-
Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics. 2012 May; 129(5):809-14.
Score: 0.014
-
H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. Am J Prev Med. 2011 Aug; 41(2):121-8.
Score: 0.013
-
Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. Arch Pediatr Adolesc Med. 2011 Aug; 165(8):749-55.
Score: 0.013
-
The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics. 2011 May; 127 Suppl 1:S45-53.
Score: 0.013
-
The Pregnancy and Influenza Project: design of an observational case-cohort study to evaluate influenza burden and vaccine effectiveness among pregnant women and their infants. Am J Obstet Gynecol. 2011 Jun; 204(6 Suppl 1):S69-76.
Score: 0.013
-
Injection site and risk of medically attended local reactions to acellular pertussis vaccine. Pediatrics. 2011 Mar; 127(3):e581-7.
Score: 0.013
-
Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health. 2009 Oct; 99 Suppl 2:S389-97.
Score: 0.011
-
Validation of a screening instrument to identify persons for exclusion from smallpox vaccination. Clin Infect Dis. 2005 Feb 15; 40(4):620-3.
Score: 0.008
-
Detecting possible vaccination reactions in clinical notes. AMIA Annu Symp Proc. 2005; 306-10.
Score: 0.008